Delivery Order SPE2DB25D3108-SPE2DB25FPCSM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Xolair 150 mg/ml syringes, with a firm fixed price ceiling value of $6,483.06 and an ultimate completion date of June 24, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under the company's larger pharmaceutical supply framework with the federal government. The place of performance is listed as AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. The contract, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, was awarded on a non-competitive, firm fixed-price basis. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a $34,576.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xolair 150 mg/ml syringes. This non-set-aside competitive award is scheduled for completion by June 24, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of XOLAIR 150 mg/ml syringes, with an ultimate completion date of August 1, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The award was issued on July 11, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $5,762.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xolair 150 mg/ml syringes. This non-competitive delivery order, which must be completed by May 15, 2025, represents a child task order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The delivery will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,881.36 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringe. The contract is a firm fixed price delivery order with an ultimate completion date of June 17, 2025, and represents a competitively awarded, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's...
- The Defense Logistics Agency awarded a Delivery Order valued at $1,440.70 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under a larger indefinite delivery contract vehicle. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPCSMDelivery Order
The Defense Logistics Agency awarded a $2,161.02 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xolair 150 mg/ml syringes, with completion scheduled for May 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under AmerisourceBergen's comprehensive pharmaceutical supply agreement with DLA, valued at $999,999,999.00 and extending through December 2026. The prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs globally. Xolair (omalizumab), a monoclonal antibody used primarily for moderate-to-severe allergic asthma and chronic idiopathic urticaria, represents the type of specialty medication that AmerisourceBergen routinely procures for the Defense Health Agency and other federal healthcare systems under this flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 4/24/25 |